Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VoferonL with ropivacaine for incision-site pain after laparoscopic colorectal cancer surgery
KCT0012200Phase 3Completed
- Sponsor
- JP Cares
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ropivacaine in colorectal cancer (CRC) (2 arms), sponsored by JP Cares. Primary endpoints: Reduction in postoperative analgesic use and Incision-site pain relief. Started Aug 2023; status: completed.
02
Drugs
ropivacaine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on KCT0012200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012200.